At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Acamprosate +2 moredrug
Likely dose
Acamprosate 333mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Medication Development in Protracted Abstinence in Alcoholism: Acamprosate Versus Naltrexone
In Brief
A Phase 2 clinical trial evaluating Acamprosate, Naltrexone, and 1 other intervention for Alcoholism. Completed, enrolled 68 participants across 1 site.
Detailed Summary
The purpose of this study is to develop and validate a human laboratory model for prediction of medication efficacy in clinical trials for relapse prevention in alcohol dependence.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcoholism
CountriesUnited States
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2007
First PostedApr 2008
Primary CompletionJan 2010
TodayJul 2026
First PostedApr 11, 2008
Enrollment StartDec 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.2 years ago
Interventions
Acamprosatedrug
Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
Naltrexonedrug
50mg capsule, Once daily, 1 week duration
Placebodrug
Matched placebo capsule, 1 week duration